Larotrectinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), CHUIKYO (Japan) and DMC (Denmark), among others, recommended or restricted larotrectinib, while NYE METODER (Norway) did not recommend it.
Assessment has run over 6.1 years, from 1 Aug 2019 at AWMSG (Wales) to 26 Sep 2025 at CONITEC (Brazil).
CONITEC (Brazil) changed its position: not recommended on 7 Dec 2021, recommended by 26 Sep 2025, after a resubmission.
No assessment is on file from SMC (Scotland) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 8 of 29 records date from 2023 or later.
4 distinct indication wordings are recorded for larotrectinib by the agencies that label one in English (AWMSG, NICE and PBAC).
6 of these 29 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess larotrectinib, on 1 Aug 2019; DMC (Denmark) did not open a file until 18 Jun 2025 — a wide spread of 5.8 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
8 of the 14 agencies here assessed larotrectinib more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
larotrectinib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for larotrectinib reads 14 recommended, 7 not recommended, 2 deferred and 2 restricted, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 26 Sep 2025 | Pacientes pediátricos com tumores sólidos localmente avançados ou metastáticos positivos para fusão do gene NTRK. | incorporated into SUS | source |
| DMC (Denmark) | 18 Jun 2025 | NTRK-fusion-positive solide tumorer | Anbefalet | source |
| NYE METODER (Norway) | 27 Apr 2025 | Behandling av barn under 18 år med solide tumorer med et nevrotrofisk tropomyosin-reseptorkinase (NTRK) fusjonsgen (se m… | decision recorded | source |
| PBAC (Australia) | 2023 | Solid tumours harbouring | neurotrophic receptor tyrosine | kinase (NTRK) gene fusions | Not Applicable | source |
| HAS (France) | 9 Jul 2020 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
24 further decisions for larotrectinib, across 13 agencies, are not shown here. They link to 15 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 29 decisions for larotrectinib from 14 agencies, 2019 to 2025. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.